Article Versions Notes

Koguchi D, Matsumoto K, Ikeda M, Shimizu Y, Nakamura M, Shiono Y, Katsumata H, Sato Y, Iwamura M. Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy. International Journal of Molecular Sciences. 2022; 23(20):12119. https://doi.org/10.3390/ijms232012119

Koguchi, Dai, Kazumasa Matsumoto, Masaomi Ikeda, Yuriko Shimizu, Marie Nakamura, Yutaka Shiono, Hiroki Katsumata, Yuichi Sato, and Masatsugu Iwamura. 2022. "Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy" International Journal of Molecular Sciences 23, no. 20: 12119. https://doi.org/10.3390/ijms232012119

Koguchi, D., Matsumoto, K., Ikeda, M., Shimizu, Y., Nakamura, M., Shiono, Y., Katsumata, H., Sato, Y., & Iwamura, M. (2022). Gemcitabine–Paclitaxel Chemotherapy for Patients with Advanced Urothelial Cancer Refractory to Cisplatin-Based Chemotherapy: Predictive Role of PGK1 for Treatment Response to Cytotoxic Chemotherapy. International Journal of Molecular Sciences, 23(20), 12119. https://doi.org/10.3390/ijms232012119